A monthly audio round-up detailing the contents of the latest issue of DTB. For 50 years, Drug and Therapeutics Bulletin (DTB) has provided rigorous and independent evaluations of, and practical advice on, individual treatments and the overall management of disease for doctors, pharmacists and other healthcare professionals. DTB has always been wholly independent of the pharmaceutical industry, Government and regulatory authorities. DTB is also free of advertising and other forms of commercial sponsorship. Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page - https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309. * The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement, patient care or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast...
https://dtbbmj.podbean.com
Mixtard 30
As part of DTB’s “Don’t Drop Mixtard” campaign, this podcast discusses the implications of the drug’s withdrawal from the UK market for people with diabetes, healthcare professionals and the NHS.
The conversation involves Dr Wing May Kong (consultant endocrinologist and member of the DTB Editorial Board), Cathy Moulton (Care Adviser at Diabetes UK), and Dr Ike Iheanacho and David Phizackerley (Editor and Deputy Editor of DTB, respectively).
To find out more about the campaign, including DTB’s petition against the withdrawal of Mixtard 30, please go to dtb.bmj.com.